Currently, dialysis is a treatment used to clear the blood of waste products when the kidneys are functioning below normal levels. This type of treatment would also help the patients with acute-on-chronic liver failure (ACLF), but an effective ‘liver dialysis device’ does not exist.
To meet this need, the ALIVER Consortium has developed and optimised a novel ‘liver dialysis device’, DIALIVE. The DIALIVE device is protected by worldwide patents and is based upon our discovery that:
(i) albumin, a circulating protein involved in detoxification, has irreversibly reduced function in ACLF
(ii) endotoxemia (a build-up of endotoxins in the blood) contributes to an increased risk of infection in liver failure.